TelyRx to Present at Global Technology Virtual Investor Conference

TelyRx Holdings Inc. (TSX: TELY, OTCQX: TELYF), a technology-enabled healthcare and online pharmacy platform, announced it will make a significant presentation at the Global Technology Virtual Investor Conference on July 9, 2026. Vanessa Slowey, President and Chief Executive Officer (CEO), and John Cascio, Chief Financial Officer (CFO), will participate in the live event, detailing TelyRx's operational expansion and robust financial growth across the United States.

The company recently achieved a significant operational milestone by surpassing one million prescriptions filled nationwide since its inception. This achievement highlights the increasing demand for TelyRx's digital pharmacy model and its growing market acceptance. TelyRx also reported a remarkable 35% sequential revenue growth in the first quarter of 2026 compared to the prior quarter. The company commenced trading on the Toronto Stock Exchange (TSX) under the symbol TELY in April 2026 and on the OTCQX Best Market, a premier tier of the OTC Markets Group in the U.S., under the symbol TELYF in June 2026. TelyRx positions itself as a technology-enabled healthcare and online pharmacy platform, providing access to over 450 FDA-approved medications across 48 U.S. states and territories.

Such virtual investor conferences serve as crucial platforms for companies to engage directly with individual and institutional investors, advisors, and analysts globally. TelyRx's listing on OTCQX facilitates easier access for U.S. investors to the company's shares, and this presentation aims to foster transparency and direct communication with the investment community. The escalating consumer demand for digital healthcare services and the expansion of the cash-pay prescription market further amplify the market impact of platforms like TelyRx.

As digitization accelerates within the U.S. healthcare sector, patients are increasingly seeking easier access to medications, transparent pricing, and more convenient solutions. TelyRx's cash-pay model, which eliminates insurance complexities, directly addresses these needs. The cash-pay prescription market, representing the fastest-growing segment of the approximately $806 billion U.S. prescription drug market, provides a significant macroeconomic context supporting TelyRx's growth potential. The company's focus on primarily dispensing generic medications allows it to offer affordable solutions, reaching a broad consumer base.

Market analysts and investors will likely view TelyRx's upcoming presentation as an opportunity to gain deeper insights into the company's rapid growth strategies and the future potential of its digital pharmacy model. The company's management has demonstrated operational success, not only by reaching the one million prescription milestone but also through strong revenue growth in the previous quarter. Moving forward, TelyRx's capacity to strengthen its position in the U.S. healthcare market and generate long-term shareholder value may become clearer through such investor engagements.